Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC-841 in healthy adults
NCT06219499Phase 1Withdrawn
- Sponsor
- OncoC4
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial in solid tumor comparing Placebo with ONC-841 (2 arms). Primary endpoints: Dose Limiting Toxicity at 42 Days and Maximum Tolerated Dose at 42 Days. Planned start Jun 2024; status: withdrawn.
02
Drugs
ONC-841
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06219499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219499.